...less medical jargon in a 'Quick Glance' format!
Adalimumab side effects:
redness, itching, bruising, pain, or swelling in the place of injection
Some side effects can be serious. The following symptoms are uncommon, but if you experience any of them or those listed in the IMPORTANT WARNING section, call your doctor immediately:
numbness or tingling
problems with vision
weakness in legs
shortness of breath
rash, especially a rash on the cheeks or arms that is sensitive to sunlight
new joint pain
swelling of the face, feet, ankles, or lower legs
difficulty breathing or swallowing
fever, sore throat, chills, and other signs of infection
unusual bruising or bleeding
Using this drug may increase the risk of developing certain types of cancers including lymphoma. People who have had severe rheumatoid arthritis for a long time may have a greater than normal chance of developing these cancers even if they do not use this drug. Talk to your doctor about the risks of using this medication.
Adalimumab is an injectable protein that blocks the inflammatory effects of tumor necrosis factor alpha (TNF alpha) in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn 's disease of the intestine. Inflammation is the body's reaction to injury and is a necessary process for the repair of injury. TNF is a protein that the body produces when there is inflammation. The TNF promotes inflammation and the signs of inflammation, which, in the case of arthritis, include fever as well as pain, tenderness, and swelling of joints. In the case of Crohn's disease, the signs of inflammation include fever, abdominal pain, and diarrhea. The unchecked inflammation of rheumatoid arthritis eventually leads to destruction of the joints. The inflammation in Crohn's disease can lead to strictures of the intestine or intestinal perforation. .Adalimumab is a synthetic protein, similar to human protein, that binds to TNF in the body and thereby blocks the effects of TNF. As a result, inflammation and its consequences in the joints and intestine are reduced. In arthritis, the progressive destruction of the joints is slowed or prevented. Adalimumab was approved by the FDA in December, 2002.